WEGO
WEGO
Shandong Weigao Group Medical Polymer Products Co. and its subsidiaries are principally engaged in the research and development
Shandong Weigao Group Medical Polymer Products Co. and its subsidiaries are principally engaged in the research and development, manufacture and sale of disposable medical devices. We provide different kinds of products, including: i) consumables (infusion sets, syringes, medical needle products, blood bags, pre-filled syringes, blood collection products and other consumables used); ii) bone materials and iii) blood purification consumables and equipment. The Company is the industrialization base of the achievements of the National High Technology Research and Development (863) Program of China, a national high-tech enterprise and a national enterprise technology center. The main production base of the Group is located in Weihai City, Shandong Province, the PRC.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Aug 09, 2020 12:23 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Healthcare
NK Celltech Receives a Series A Round of Funding Worth More Than CNY 100 Million
NK Celltech recently received a Series A round of funding totaling more than CNY 100 million. Huagai Capital led this round of funding, which was followed by CASVC, Unifortune, 呈益资本, Sirius Capital, and QJ Capital.
Jul 01, 2022 03:58 PM
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Jun 23, 2022 10:20 AM
· Healthcare
Huashen Zhiyao completed nearly 500million yuan of a-round financing and went deep into AI new drug development
Briefing Jun 23, 2022 10:15 AM
· Healthcare
Huamei Haolian, a health management service enterprise, completed round a+ financing, and Jinshajiang venture capital led the investment
Briefing Jun 23, 2022 10:06 AM
· Healthcare
Mojia biology announced the completion of round B financing
Briefing Jul 20, 2021 03:33 PM
· Technology
Ruiyuan Zhao Feng position announced in the second quarter, Xiaomi group is still the largest position stocks
See more
Related Companies
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.